GlassScriptPhysician profile
David L Kading
NPI 1013029719
$396,755.30
in general payments reported to CMS, 2019-2025
32 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $44K · 2021: $54K · 2022: $137K · 2023: $73K · 2024: $25K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $32K · Consulting Fee: $28K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $6,685 · Grant: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $31,925.62 |
| Consulting Fee | $28,302.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,175.00 |
| Food and Beverage | $12,720.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,585.00 |
| Travel and Lodging | $6,685.07 |
| Grant | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $114,131.70 | 2019-2025 | Meibomian Gland Evaluator, Lipiflow System Activator (Disposable), Lipiflow System Activator II (Disposable |
| Carl Zeiss Meditec, INC. | $58,751.57 | 2019-2022 | |
| Oculus, INC. | $38,615.03 | 2022-2025 | Myopia Master, Pentacam Axl Wave, Na |
| Bausch & Lomb Americas INC. | $34,681.03 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Allergan, INC. | $32,177.30 | 2019-2022 | |
| Abbvie INC. | $20,504.57 | 2022-2025 | |
| Alcon Vision LLC | $20,260.58 | 2019-2023 | |
| Lumenis Be INC | $18,150.00 | 2022-2023 | Optilight |
| Kala Pharmaceuticals, INC. | $10,801.12 | 2021 | |
| Shire North American Group INC | $8,111.18 | 2019 | |
| Coopervision INC. | $6,635.20 | 2020-2025 | Misight Contact Lens |
| Eyevance Pharmaceuticals LLC | $6,321.43 | 2019-2021 | |
| Thea Pharma INC. | $5,874.52 | 2022-2023 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $5,830.77 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $4,219.46 | 2019-2023 | Cequa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tearlab Corp | $3,950.00 | 2021-2023 | Tearlab Osmolarity System |
| Dompe US, INC. | $2,982.32 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $1,953.47 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,363.89 | 2019-2021 | |
| Visioneering Technologies, INC. | $500.00 | 2024 | |
| Visionary Optics LLC | $300.00 | 2022 | |
| Valley Contax, INC. | $200.00 | 2020 | |
| Mallinckrodt Enterprises LLC | $124.96 | 2019 | |
| Quidel Corporation | $113.89 | 2019 | |
| Oyster Point Pharma, INC. | $55.59 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $50.92 | 2025 | Xdemvy |
| Heru, INC. | $28.63 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $17.58 | 2021 | |
| Horizon Therapeutics Plc | $15.55 | 2023 | Tepezza |
| Sight Sciences, INC. | $13.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kading listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.